cor2ed
engage checkpoint medical linkedin twitter
bg

New therapies for metastatic hormone sensitive prostate cancer

New therapies for metastatic hormone sensitive prostate cancer

Prof. David Pfister

As an experienced urologist and member of GU CONNECT, Prof. David Pfister provides his perspective on new therapies for mHSPC.
Portrait of David Pfister
Prof. David Pfister

Urologist

University Hospital of Cologne

Germany

preview next

time Expert View | open 5 min | 2019

download resources

I agree that this educational programme:

GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.

Other programmes of interest

preview next